Slide 1: Corporate Presentation
Corporate presentation September 2016 For personal use only Cover sheet to be added – Simone Corporate Presentation October 2019 David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain R
Slide 2: Who is Compumedics?
Who is Compumedics? For personal use only A leading global, innovative developer and manufacturer of medical devices for: Monitoring neurological Ultrasonic monitoring of Diagnosing disorders including long- Highly sophisticated blood flow through the sleep disorders term epilepsy monitoring brain r
Slide 3: 6 reasons to buy Compumedics
6 reasons to buy Compumedics For personal use only 1 Proven and established MedTech leader in its chosen markets with strong balance sheet and sound growth strategy 2 Core markets in sleep and neuro diagnostics / monitoring offer solid growth platform 3 Multiple upside “New Generation” incremental s
Slide 4: Core Business – Premium Focus
Core Business – Premium Focus For personal use only Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Research Global market – 250m 1,300m 20m 15m USD pa Compumedics market share 6% <1% 30% 35% (approximate) Aust – 1 Aust – 1 Aust – 1 Aust – 1 Compumedics
Slide 5: Diversified Product Portfolio
Diversified Product Portfolio For personal use only 5
Slide 6: Revenue Composition at $18.0m for H1 FY21
Revenue Composition at $18.0m for H1 FY21 31 December 2020 – half year For personal use only By geographic region By product/market Customer Care 9% Consumables 11% Europe, USA, Sleep - 30% 29% Clinical Brain - Blood Flow Diagnostics Monitoring 23% 24% Sleep - Nexus360 Aust, 2% Brain - Asia, 14% Res
Slide 7: Pandemic resilient
For personal use only Pandemic resilient 7
Slide 8: Growth Platform – Core and Step-Out
Growth Platform – Core and Step-Out For personal use only Sales – schematic only FY19A FY20A FY21F FY22F FY23F Core - Base Core - Sleep/Neuro (Mid Market) Neuro - MEG Sleep - eHealth (Nexus360 & Somfit) • Step-out - NEURO – BRAIN IMAGING – First phase installation at Barrow Neurological Institute in
Slide 9: Next Generation Growth – Core and Step-out
Next Generation Growth – Core and Step-out For personal use only Neuro Sleep Neuro Brain Blood Diagnostics – Diagnostics Diagnostics - Imaging Flow Diagnostics Clinic Cloud based sleep Long term epilepsy Leverage existing TCD Leverage CURRY Next generation diagnostic platforms for market penetration
Slide 10: Core Business - Growth Drivers
Core Business - Growth Drivers For personal use only Compumedics/Neuroscan innovative brain analysis software and high-performance amplifiers are unrivalled world class technology. Curry 9 releasing FY21 We have about 23,000 systems installed worldwide. Strong reputation and brand name. Customers li
Slide 11: New products launching in late 2021, early 2022
New products launching in late 2021, early 2022 For personal use only 11
Slide 12: The basis for our movement to digital / eHealth
The basis for our movement to digital / eHealth For personal use only 12
Slide 13: Step out - Brain Imaging
Step out 1 - Brain Imaging: For personal use only Opportunity Market & Competition Plan Outcome CMP’s CURRY brain analysis The MEG market is currently estimated Calendar 2021 – second CMP has sold and software is already the gold at about 20 systems a year at an and final phase of MEG partially inst
Slide 14: Step out - eHealth – Cloud Sleep Diagnostics
Step out 2 - eHealth – Cloud Sleep Diagnostics For personal use only Nexus 360 Operational systems have been Compumedics is Key partners (professional developed for the cloud-based continuing to seek being pursued cloud sleep capture, transfer appropriate third include web, diagnostics) sold and tra
Slide 15: Directors & Executive Team
Directors & Executive Team Key Management For personal use only David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 32 yrs Mr Tucson Dunn Mr. David Lawson Non Executive Director Chief Financial Officer CMP Tenure 12 months & Company Secretary CMP Tenure 20 yrs Mr. Warwick Freeman Kerry Hubic
Slide 16: Investor Summary
Investor Summary Core business profitable with on-going growth For personal use only opportunities in key global markets International sales force Compumedics remains expansion, neurology and sleep committed to continuing to market opportunity and earnings deliver superior returns to improvement ini
Slide 17: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Compumedics Ltd (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability o
Slide 18: compumedics.com.au
For personal use only compumedics.com.au 18